Form 4: Monopar Therapeutics CFO Granted 25,000 Stock Options

Quan Anh Vu, Chief Financial Officer of Monopar Therapeutics, was granted 25,000 stock options on March 3, 2025, according to a Form 4 filing.

Summary

• A Form 4 filing reveals that Quan Anh Vu, the Chief Financial Officer of Monopar Therapeutics, received 25,000 stock options on March 3, 2025.
• The exercise price of these options is $30.93.
• The options vest in installments, with 15,625 shares vesting on September 2, 2025, and the remainder vesting monthly until March 3, 2029.
• The options expire on March 2, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own. It's a standard practice for executive compensation.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key executives and align their interests with those of shareholders. The vesting schedule encourages long-term commitment to the company's success.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules typically range from three to five years, aligning with the time horizon for drug development and commercialization.
• The size of the grant is generally benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, indicating that the company is investing in its leadership.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Form 4, Monopar Therapeutics, MNPR, Quan Anh Vu, CFO, insider trading